Zosano Pharma Corporation (NASDAQ:ZSAN) Shorts Declined By 43.02%

June 29, 2018 - By Robert Case

It was registered a decrease on Zosano Pharma Corporation (NASDAQ:ZSAN)’s shares shorted with 43.02%. FINRA announced shares shorted of ZSAN’s total 924,200 shares. That’s 43.02% down from 1.62 million shares. 2 days will cost ZSAN with 523,600 average volume to restore its previous position. 2.89% is Zosano Pharma Corporation float short.

The stock increased 2.01% or $0.08 during the last trading session, reaching $4.06.Currently Zosano Pharma Corporation is downtrending after 85.30% change in last June 29, 2017. ZSAN has 185,578 shares volume. ZSAN underperformed the S&P 500 by 97.87%.

Zosano Pharma Corporation, a clinical stage pharmaceutical company, develops a proprietary intracutaneous delivery system to administer drugs through the skin for rapid symptom relief to patients.The firm is valued at $48.61 million. The Company’s lead product candidate is M207, a proprietary formulation of zolmitriptan used for the treatment of migraine.Last it reported negative earnings.

For more Zosano Pharma Corporation (NASDAQ:ZSAN) news brought out recently go to: Benzinga.com, Benzinga.com, Streetinsider.com, Streetinsider.com or Nasdaq.com. The titles are as follows: “60 Biggest Movers From Yesterday” brought out on June 19, 2018, “20 Stocks Moving In Thursday’s Pre-Market Session” on June 28, 2018, “After-Hours Stock Movers 06/27: (EDGE) (ZSAN) (MSG) Higher; (PIR) (BBBY) (XON) Lower (more…)” with a publish date: June 27, 2018, “UPDATE: BTIG Starts Zosano Pharma (ZSAN) at Buy” and the last “Zosano Announces Publication on Adhesive Dermally-Applied Microarray (ADAMâ„¢) Technology for the Delivery of …” with publication date: June 20, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: